Context Therapeutics (CNTX) Insider Trading & Ownership $0.72 +0.04 (+6.70%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Context Therapeutics (NASDAQ:CNTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.80%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$107.21KNumber OfInsiders Selling(Last 12 Months)0 Get CNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Context Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CNTX Insider Buying and Selling by Quarter Context Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/9/2025Martin A LehrCEOBuy100,000$0.70$70,000.00 6/6/2025Alex C LevitInsiderBuy20,000$0.58$11,600.00 6/6/2025Jennifer Lynn Minai-AzaryCFOBuy40,010$0.64$25,606.40 (Data available from 1/1/2013 forward) CNTX Insider Trading Activity - Frequently Asked Questions Who is on Context Therapeutics' Insider Roster? The list of insiders at Context Therapeutics includes Alex C Levit, Jennifer Lynn Minai-Azary, and Martin A Lehr. Learn more on insiders at CNTX. What percentage of Context Therapeutics stock is owned by insiders? 2.80% of Context Therapeutics stock is owned by insiders. Learn more on CNTX's insider holdings. Which Context Therapeutics insiders have been buying company stock? The following insiders have purchased CNTX shares in the last 24 months: Alex C Levit ($11,600.00), Jennifer Lynn Minai-Azary ($25,606.40), and Martin A Lehr ($70,000.00). How much insider buying is happening at Context Therapeutics? Insiders have purchased a total of 160,010 CNTX shares in the last 24 months for a total of $107,206.40 bought. Context Therapeutics Key ExecutivesMr. Martin A. Lehr (Age 40)Co-Founder, President, CEO & Director Compensation: $674.08k1 recent tradesMs. Jennifer Minai-Azary (Age 46)CFO & Treasurer Compensation: $504.14k1 recent tradesMr. Alex C. Levit Esq. (Age 45)Chief Legal Officer & Corporate Secretary Compensation: $483.83k1 recent tradesMr. Christopher Beck M.B.A.Senior Vice President of Operations More Insider Trading Tools from MarketBeat Related Companies SLRN Insider Selling TVGN Insider Selling MNPR Insider Selling SLS Insider Selling EDIT Insider Selling DSGN Insider Selling SCPH Insider Selling KOD Insider Selling CRGX Insider Selling LRMR Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling Hits Market Leaders—Should You Be Worried?3 Small Caps Drawing Insider and Institutional SupportDo They Know Something? Insiders & Congress Buy UnitedHealthMicron Insiders Sell But Investors Should Buy, Buy, BuySizzling Insider Buys for Your High-Yield Watchlist This page (NASDAQ:CNTX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredIt’s game over when Elon rolls this outElon Musk says his upcoming innovation could be the "biggest product of all time"... And by the looks of th...InvestorPlace | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
